Cargando…

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States

BACKGROUND: Benign prostatic hyperplasia (BPH) is a common disease in men that is characterized by lower urinary tract symptoms. Pharmacologic treatment with alpha blockers (ABs) and 5-alpha reductase inhibitors (5ARIs) is recommended to alleviate symptoms, prevent disease progression that can lead...

Descripción completa

Detalles Bibliográficos
Autores principales:	DerSarkissian, Maral, Xiao, Yongling, Duh, Mei Sheng, Lefebvre, Patrick, Swensen, Andrine R., Bell, Christopher F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397950/ https://www.ncbi.nlm.nih.gov/pubmed/27668569 http://dx.doi.org/10.18553/jmcp.2016.22.10.1204

Ejemplares similares

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016)

Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study
por: Laanani, Moussa, et al.
Publicado: (2023)

The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis
por: Li, Yao, et al.
Publicado: (2022)

The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model
por: Da Silva, Marcello H A, et al.
Publicado: (2018)

Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride
por: Khedmati, Jamaleddin, et al.
Publicado: (2021)

Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials
por: Zhou, Zhongbao, et al.
Publicado: (2020)

Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2013)

The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia
por: Sullivan, Michael J, et al.
Publicado: (2002)

Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride
por: Kiguradze, Tina, et al.
Publicado: (2017)

The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride
por: Choi, Yong Hyeuk, et al.
Publicado: (2010)

Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
por: Eisen, Christoph, et al.
Publicado: (2020)

A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride
por: Antoniou, Tony, et al.
Publicado: (2018)

Bone Health Risks Associated with Finasteride and Dutasteride Long-Term Use
por: Sirufo, Maria Maddalena, et al.
Publicado: (2021)

Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Nigerian Men with Benign Prostatic Hyperplasia
por: Odusanya, Benjamin O, et al.
Publicado: (2017)

The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Finasteride in the treatment of patients with benign prostatic hyperplasia: a review
por: Smith, Angela B, et al.
Publicado: (2009)

Does treatment with dutasteride or finasteride has impact on renal morphology? Experimental study
por: da Silva, Marcello Henrique Araújo, et al.
Publicado: (2021)

Reproductive and endocrinological effects of Benign Prostatic Hyperplasia and finasteride therapy in dogs
por: Angrimani, Daniel S. R., et al.
Publicado: (2020)

Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm
por: Traish, Abdulmaged M.
Publicado: (2020)

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia
por: Thomson, Andrew
Publicado: (2005)

Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia
por: Shin, Yu Seob, et al.
Publicado: (2019)

Frozen-Thawed Sperm Analysis of Benign Prostatic Hyperplasia Dogs Treated With Finasteride
por: Flores, Renato Bueno, et al.
Publicado: (2022)

Alteration of Gut Microbes in Benign Prostatic Hyperplasia Model and Finasteride Treatment Model
por: An, Jinho, et al.
Publicado: (2023)

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
por: Seok, Jaekwon, et al.
Publicado: (2023)

The Effect of Finasteride and Dutasteride on the Growth of WPE1-NA22 Prostate Cancer Xenografts in Nude Mice
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2012)

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
por: Toren, Paul, et al.
Publicado: (2013)

Finasteride in the treatment of clinical benign prostatic hyperplasia: A systematic review of randomised trials
por: Edwards, Jayne E, et al.
Publicado: (2002)

Does finasteride treatment for benign prostatic hyperplasia influence sperm DNA integrity in dogs?
por: Angrimani, Daniel S. R., et al.
Publicado: (2020)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study
por: Choi, Gwang-Seong, et al.
Publicado: (2022)

Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus
por: Elkelany, Osama O, et al.
Publicado: (2015)

Combination therapy with curcumin plus tamsulosin and finasteride in the treatment of men with benign prostatic hyperplasia: a single center, randomized control study
por: Qiao, Jing, et al.
Publicado: (2021)

Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy
por: Cai, Tong, et al.
Publicado: (2020)

Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors – dutasteride and finasteride – in the presence of testosterone
por: Hatanaka, Toshiki, et al.
Publicado: (2021)

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
por: Barkin, Jack
Publicado: (2011)

Changes in Sexual Function in Benign Prostatic Hyperplasia Patients Taking Dutasteride: 1-Year Follow-Up Results
por: Chi, Byung Hoon, et al.
Publicado: (2011)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
por: Djavan, Bob, et al.
Publicado: (2011)

Removal of ineligible outcome cases reduces confounding
por: Walker, Alexander M, et al.
Publicado: (2018)

Ramelteon combined with an α(1)-blocker decreases nocturia in men with benign prostatic hyperplasia
por: Kawahara, Takashi, et al.
Publicado: (2013)

Update on the use of dutasteride in the management of benign prostatic hypertrophy
por: Miller, Joe, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_tatufle0q591b7gresj5502lma